HMG

In its actual medical role it drives the gonads directly: in women it induces ovulation (FSH grows the follicles, the LH activity supports the final maturation), and in men with hypogonadotropic hypogonadism it restores sperm production. The community use is the male-fertility one — people pair it with HCG to rebuild full testicular function. The honest framing up front: the fertility indications are genuinely clinical, but the specific protocols people run to ‘restore fertility’ off-cycle are extrapolated from that clinical use, not validated as their own thing.

The reason it exists in the conversation at all is a gap HCG leaves. HCG mimics LH — it tells the testes to make intratesticular testosterone, which is most of what keeps them full and functional. But LH signaling alone doesn’t reliably drive spermatogenesis; that job belongs to FSH acting on Sertoli cells. HMG supplies that FSH activity. So the community framing is clean and largely correct: HCG handles the testosterone-and-volume side, HMG (or a purified/recombinant FSH) handles the sperm-production side, and the two together is what the clinical literature actually uses to induce spermatogenesis in men whose own pituitary signal is gone — including after long testosterone or steroid suppression.

It’s a direct gonadotropin replacement, working below the brain entirely — it doesn’t nudge your own axis, it substitutes for its output. FSH activity binds FSH receptors (on ovarian granulosa cells in women, on testicular Sertoli cells in men) to drive follicle growth and spermatogenesis respectively. The LH activity binds LH receptors (thecal cells in women, Leydig cells in men) to drive steroidogenesis. Worth knowing where the LH activity actually comes from: in urinary HMG it’s largely contributed by hCG concentrated from postmenopausal urine during purification, and modern preparations are standardized to roughly 75 IU FSH and 75 IU LH activity per ampoule. Because it replaces the signal rather than restarting it, it does nothing to recover a suppressed hypothalamic-pituitary axis on its own.

These are the usual gonadotropin side effects, and they’re real. In women the headline risk is ovarian hyperstimulation syndrome (OHSS) — ovaries enlarge and fluid shifts into the abdomen; mild forms are common and severe forms are a medical emergency — plus a markedly raised chance of multiple pregnancy. In men, gonadotropin therapy is generally better tolerated but can bring injection-site reactions, gynecomastia (from the rise in estradiol as testosterone production climbs), acne, and mood changes. Across both: it’s injectable and expensive, supplied as a clinical-grade product, and like everything in this space sourced outside a pharmacy the dose and purity in the vial aren’t guaranteed — insist on a certificate of analysis. This is a hormone preparation with documented systemic effects, not a gentle nudge.

The defining pairing is with HCG — that’s the whole clinical logic, and the community follows it: HCG to drive intratesticular testosterone and testicular volume, HMG (or a purified/recombinant FSH) to supply the FSH activity that actually produces sperm. It shows up in post-cycle and fertility-restoration contexts for exactly that reason, often after stopping testosterone or anabolic steroids that suppressed the axis. It is not stacked for performance or body composition — there’s no plausible use there, since it’s a direct gonadotropin replacement aimed at fertility.